Genome&Company
KOSDAQ:314130
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genome&Company
KOSDAQ:314130
|
KR |
|
S
|
Siam City Cement PCL
SET:SCCC
|
TH |
|
W
|
Winix Inc
KOSDAQ:044340
|
KR |
|
T
|
Taewoong Co Ltd
KOSDAQ:044490
|
KR |
|
Nano Magic Holdings Inc
OTC:NMGX
|
US |
|
A
|
APT Moto Vox Group Inc
OTC:MTVX
|
US |
|
V
|
Veritas In Silico Inc
TSE:130A
|
JP |
|
J
|
JNTC Co Ltd
KOSDAQ:204270
|
KR |
|
P
|
Prisma Properties AB
STO:PRISMA
|
SE |
|
MYT Netherlands Parent BV
NYSE:LUXE
|
DE |
|
S
|
Stilo Energy SA
WSE:STI
|
PL |
|
Waseco Resources Inc
XTSX:WRI
|
CA |
|
F
|
Focus Impact Acquisition Corp
OTC:FIAC
|
US |
|
C
|
Chemtros Co Ltd
KOSDAQ:220260
|
KR |
|
L
|
Lerthai Group Ltd
HKEX:112
|
HK |
|
Hall of Fame Beverages Inc
OTC:HFBG
|
US |
|
C
|
Capital Engineering Network PCL
SET:CEN
|
TH |
|
B
|
Boldt SA
BCBA:BOLT
|
AR |
|
P
|
Photo-Me International PLC
F:PHQ
|
UK |
Shareholder Yield
Current shareholder yield for Genome&Company is hidden .
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
Price
Genome&Company
| Average Annual Return | -35.6% |
| Standard Deviation of Annual Returns | 23.77% |
| Max Drawdown | -92% |
| Market Capitalization | 199.4B KRW |
| Shares Outstanding | 44 710 000 |
| Percentage of Shares Shorted |
N/A
|
Return Decomposition
Main factors of price return
Stock Splits
Genome&Company's latest stock split occurred on Aug 6, 2024
The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.
Before the split, Genome&Company traded at 8380 per share. Afterward, the share price was about 4530.
The adjusted shares began trading on Aug 6, 2024. This was the only stock split in Genome&Company's history.
